$150M equity raise priced at $10 per share drove 15% stock decline.
Context
What happened: Vir Biotechnology (VIR) priced an underwritten public offering of 15M common shares at $10 per share, with expected gross proceeds of $150M. Underwriters have a 30-day option for up to 2.25M additional shares.
Key numbers: 15M shares at $10 per share, $150M expected gross proceeds, 30-day option for up to 2.25M additional shares, stock down 15%.
Why it matters: The stock fell 15% after the pricing, reflecting the dilution from the offering.
What changed
Vir Biotechnology (VIR) priced an underwritten public offering of 15M common shares at $10 per share, with expected gross proceeds of $150M. Underwriters have a 30-day option for up to 2.25M additional shares.